Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $36.35 and last traded at $30.24, with a volume of 16241600 shares traded. The stock had previously closed at $4.63.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on MNPR shares. HC Wainwright lifted their target price on shares of Monopar Therapeutics from $2.00 to $6.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 target price on the stock.
Check Out Our Latest Report on Monopar Therapeutics
Monopar Therapeutics Stock Performance
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). As a group, analysts expect that Monopar Therapeutics Inc. will post -1.93 earnings per share for the current fiscal year.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Featured Articles
- Five stocks we like better than Monopar Therapeutics
- What Are Trending Stocks? Trending Stocks Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Pros And Cons Of Monthly Dividend Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 3 Healthcare Dividend Stocks to Buy
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.